CYRX

In the past six months, Cryoport, Inc. (CYRX) stock increased 76.0% year-to-date and 7.51% over the last three months as of October 8, 2026. Key earnings reports include Q4 2025 results released on March 3, 2026. For Q1 2026 (May 4, 2026), revenue grew 16% year-over-year to $47.8 million, with commercial cell and gene therapy revenue up 26%, Life Sciences Services revenue up 18% (driven by 21% growth in BioStorage/BioServices), and Life Sciences Products revenue up 15%. The company supported 766 global clinical trials and 21 commercially approved CGTs, raising its full-year revenue guidance. Q2 2026 earnings (August 6, 2026) showed revenue growth of 8% year-over-year to $49.0 million, with Life Sciences Services revenue increasing 15% (BioStorage/BioServices up 25%). Cryoport supported 779 global clinical trials and 22 commercially approved CGTs, achieved positive adjusted EBITDA, but reported an EPS of -$0.20, missing analysts' estimates. Analyst ratings generally indicate a 'Moderate Buy' consensus, with one downgrade in the previous 90 days.